Trial Profile
A real world study investigating effectiveness of single dose oritavancin in patients with skin and skin structure infections by analysing hospitalization and length of stay in US hospitals
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Skin and soft tissue infections
- Focus Therapeutic Use
- 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 24 May 2017 New trial record